Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 0.96 |
| ▸ | ERBB2 known ✓ | P04626 | 20/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.81 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.81 |
| ▸ | AXL known ✓ | P30530 | 1/20 | 0.81 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.81 |
| ▸ | MAP2K2 known ✓ | P36507 | 1/20 | 0.81 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.81 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.81 |
| ▸ | MAP2K1 known ✓ | Q02750 | 1/20 | 0.81 |
| ▸ | BTK known ✓ | Q06187 | 1/20 | 0.81 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.81 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.81 |
| ▸ | STK25 | O00506 | 1/20 | 0.81 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.81 |
| ▸ | GAK | O14976 | 1/20 | 0.81 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.81 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL4963951 | 1.00 | EGFR (0.96) | EGFRERBB2STK25MAP2K7CHEK1 | |
| SCHEMBL2204372 | 0.98 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| SCHEMBL2204366 | 0.98 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL29801668 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL19579521 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL28793163 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL2180998 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL2385159 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL2385190 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Neratinib SCHEMBL29801259 | 0.93 | ERBB2 (0.95) | EGFRERBB2STK25MAP2K7CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | HCCS, CYP3A7, QPCT | EGFR 4068/4885ERBB2 3200/4885DRD2 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.